Anti-tumor vaccines

Details Anti-tumor vaccines Anti-tumor vaccines

1994-03-25

1996-12-10

Housel, James C.

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Cancer cell or component thereof

4241841, 4241741, 4241791, 4241811, A61K 39395, A61K 3900, A61K 3938, A61K 3940, A61K 3942, A61K 3944

Patent

active

055828310

ABSTRACT:
An immunogen derived from modified tumor cells and capable of inducing an anti-tumor immune response is prepared in accordance with the invention by exposing tumor cells to a crosslinking agent, which is a 2',3'-nucleoside or nucleotide dialdehyde at a concentration and for a time sufficient to cause crosslinking of proteins in the cells' plasma membranes. Improved immunogenicity may be obtained if the cells are also exposed to hydrostatic pressure at a level and for a time sufficient to cause displacement of the proteins in the cells+ plasma membranes. Exposure of the tumor cells to the crosslinking agent and to hydrostatic pressure at the same time is a preferable method of producing the immunogen. The immunogen is suitable for use as an anti-tumor vaccine for inducing an anti-tumor immune response in cancer patients.

REFERENCES:
patent: 4634590 (1987-01-01), Cohen et al.
patent: 4902288 (1990-02-01), Ingram
patent: 4931275 (1990-06-01), Shinitzky et al.
patent: 4996194 (1991-02-01), Cohen et al.
Siemann. In: Rodent Tumor Models in Experimental Cancer Therapy. ed. Kallman. pp. 12-15. Pergamon Press.
Fareed et al "Human Tumor Regression-Associated Antigenic Determinants" Human Tumor Antigens and Specific Tumor Therapy, 1989, Alan R Liss Inc, NY. pp. 317-334.
Cysyk et al "Protein Cross-Linking Properties of the Antitumor Agent Inosine Dialdehyde" Cancer Treatment reports 60(5) May 1976, pp. 563-570.
Shinitzky; "Membrane Fluidity in Malignancy--Adversative and Recuperative"; Bioch. et. Biophys. Acta, 738(1984) 251-261.
Lider et al.; "Therapeutic Vaccination Against Adjuvant Arthritis Using Autoimmune T Cells Treated with Hydrostatic Pressure"; Proc. Natl. Acad. Sci. USA, 84, pp. 4577-4580, Jul. 1987.
Ramakrishna et al., "Potentiation of Delayed-Type Hypersensitivity Response to Syngeneic Tumors in Mice Prevaccinated with Cells Modified by Hydrostatic Pressure and Crosslinking"; Can. Immunol. Immunother., 33 (1991) 1-8.
Richert et al., "Promotion of Tumor Antigenicity in EL-4 Leukemia Cells by Hydrostatic Pressure"; Can. Immunol. Immunother, 22 (1986) 119-124.
Lider et al., "Vaccination Against Experimental Autoimmune Diseases Using T Lymphocytes Treated with Hydrostatic Pressure"; Ann. N.Y. Acad. Sci., 475 (1986) 267-273.
Skornick et al., "Active Immunotherapy of Human Solid Tumor with Autologous Cells Treated with Cholesteryl Hemisuccinate"; Cancer, 58, No. 3(1986) 650-654.

Affiliated with

Also associated with

Rating

Anti-tumor vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-tumor vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-422185